Spinale Muskelatrophie im Erwachsenenalter

Die 5q-assoziierte spinale Muskelatrophie (SMA) ist eine fortschreitende autosomal rezessive Motoneuronerkrankung mit einer Inzidenz von 1:11 000 Lebendgeburten, die durch den Verlust des Survival Motor Neuron 1-Gens (SMN1) verursacht wird [1]. Additiv zur bisherigen multidisziplinären supportiven pulmonalen, gastroenterologischen, orthopädischen, neuropädiatrischen und neuromuskulären Behandlung wurden in den letzten Jahren 3 bahnbrechende erkrankungsmodifizierende Therapien der 5q-assoziierten spinalen Muskelatrophie (SMA) zugelassen, die Phänotypen und Therapielandschaft entscheidend verändert und damit neue Standards für die Beeinflussung von Neurodegeneration ermöglicht haben: Nusinersen/Spinraza als Antisense-Oligonukleotidtherapie, Onasemnogene abeparvovec/Zolgensma als eine AAV9-basierte Genersatztherapie, und Risdiplam/Evrysdi als ein „small Molecule Modifier“ des pre-mRNA Splicings.

Abstract

5q spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease affecting 1: 11000 live births and ranging from intrauterine to early adult onset. The course of the disease is progressive, the phenotype varies within a disease continuum and is mainly determined by the SMN2 copy number. So far, three disease modifying treatments (Nusinersen/Spinraza, Onasemnogene abeparvovec/Zolgensma, Risdiplam/Evrysdi) have been approved; however, gene replacement therapy with Onasemnogen abeparvovec is mainly applied from birth to toddler age. SMA treatment requires a multidisciplinary management in specialized neuromuscular centers. Since October 2021, SMA is part of the newborn screening in Germany. When SMA is clinically suspected, timely genetic diagnostics is crucial for a rapid start of treatment, since „time is motor neuron“. The different therapeutic options must be discussed with patients and families, and patient expectations must be managed. Assessment of long-term data in disease-specific registries is highly encouraged world-wide and mandatory in Germany.

Schlüsselwörter

spinale Muskelatrophie - erkrankungsmodifizierende Therapie - Neugeborenenscreening

Key words

spinal muscular atrophy - disease-modifying therapy - newborn screening

Publikationsverlauf

Artikel online veröffentlicht:
14. September 2022

• Literatur

• 1 Mercuri E, Finkel RS, Muntoni F. et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 2018; 28: 103-115
• 2 Rad N, Cai H. WeissMD. Management of spinal muscular atrophy in the adult population. Muscle Nerve 2022; online ahead of print
• 3 Butchbach ME. Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerativediseases. FrontMol Biosci 2016; 3: 7
• 4 Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015; 33: 831-846
• 5 Mercuri E. Spinal muscular atrophy: from rags to riches. Neuromuscul Disord 2021; 31: 998-1003
• 6 Jablonka S, Hennlein L, Sentner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 2022; 4: 2
• 7 Ziegler A, Wilichowski E, Schara U. et al. Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101: Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM]. Nervenarzt 2020; 91: 518-529
• 8 Kölbel H, Müller-Felber W. AWMF-Leitlinie Spinale Muskelatrophie (SMA), Diagnostik und Therapie. Im Internet: https://www.awmf.org/leitlinien/detail/ll/022-030.html (Stand: 27.06.2022)
• 9 Walter MC, Schoser B. Neue Therapien der spinalen Muskelatrophie. Akt Neurol 2018; 45: 617-624
• 10 Wirth B, Karakaya M, Kye MJ. et al. Twenty-five years of spinal muscular atrophy research: From phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet 2020; 21: 231-261
• 11 Mercuri E, Pera MC, Scoto M. et al. Spinal muscular atrophy – insights and challenges in the treatment era. Nat Rev Neurol 2020; 16: 706-715
• 12 Vill K, Schwartz O, Blaschek A. et al. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis 2021; 16: 153
• 13 Wadman RI, Wijngaarde CA, Stam M. et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol 2018; 25: 512-518
• 14 Wang CH, Finkel RS, Bertini ES. et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007; 22: 1027-1049
• 15 Finkel RS, Mercuri E, Meyer OH. et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 2018; 28: 197-207
• 16 Finkel RS, Mercuri E, Darras BT. et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 2017; 377: 1723-1732
• 17 Mercuri E, Darras BT, Chiriboga CA. et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378: 625-635
• 18 Walter MC, Wenninger S, Thiele S. et al. Safety and treatment effects of nusinersen in longstanding adult 5q-sma type 3 – a prospective observational study. J Neuromuscul Dis 2019; 6: 453-465
• 19 Hagenacker T, Wurster CD, Gunther R. et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 2020; 19: 317-325
• 20 Baranello G, Darras BT, Day JW. et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 2021; 384: 915-923
• 21 Mercuri E, Deconinck N, Mazzone ES. et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2022; 21: 42-52